Reference : Mazindol in the treatment of Parkinson's disease.
Scientific journals : Article
Human health sciences : Neurology
Social & behavioral sciences, psychology : Neurosciences & behavior
http://hdl.handle.net/2268/40238
Mazindol in the treatment of Parkinson's disease.
English
Delwaide, P. J. [> >]
Schoenen, Jean mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie >]
Martinelli, P. [> >]
1983
Archives of Neurology
American Medical Association
40
13
788-90
Yes (verified by ORBi)
International
0003-9942
1538-3687
Chicago
IL
[en] Clinical Trials as Topic ; Double-Blind Method ; Female ; Humans ; Indoles/therapeutic use ; Male ; Mazindol/therapeutic use ; Parkinson Disease/drug therapy ; Pilot Projects
[en] Mazindol, a drug that blocks the reuptake of dopamine, was studied in the treatment of Parkinson's disease in both a pilot study (12 patients) and a controlled trial (11 patients). The patients had stage II or III disease, according to the classification of Hoehn and Yahr. Both studies showed that mazindol possessed anti-parkinsonian properties and that the improvement was statistically significant. The therapeutic effect was moderate, but could be of value for patients in the early stages of the disease. The drug was well tolerated; only two patients had side effects.
http://hdl.handle.net/2268/40238

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.